Isiaka Sanni Oluwasegun*

Department of Optometry and Vision Therapy, Albasar International Foundation: Makkah Specialist Hospital Bauchi, Nigeria

*Corresponding Author: Isiaka Sanni Oluwasegun, Department of Optometry and Vision Therapy, Albasar International Foundation: Makkah Specialist Hospital Bauchi, Nigeria.

Received: April 28, 2025; Published: May 01, 2025

Abstract

Glaucoma has been regarded as a global leading cause of irreversible blindness, and therefore, significant developments in glaucoma diagnosis, monitoring, and treatment have been anticipated [1,2]. An estimated 111 million people worldwide will be affected by glaucoma by 2040, making early detection and treatment strategies a priority [1]. Recent researches have added to the understanding of the disease by providing multiparametric histopathological grading, and investigating the use of nanorobots, self-monitoring tools and drugs made for this purpose [3-5]. These scientific advances hold the potential for improved accuracy and tailor-made treatment for patients with glaucoma.

References

1. Tham YC., et al. “Global prevalence of glaucoma and projections of glaucoma burden through 2040: A systematic review and meta-analysis”. Ophthalmology11 (2014): 2081-2090.
2. Quigley HA and Broman AT. “The number of people with glaucoma worldwide in 2010 and 2020”. The British Journal of Ophthalmology3 (2006): 262-267.
3. Xiang C., et al. “Multiparametric grading of glaucoma severity by histopathology can enable post-mortem substratification of disease state”. Acta Neuropathologica Communications 1 (2025): 3.
4. Menezes Ferreira AÁ., et al. “Advancements and prospects in nanorobotic applications for ophthalmic therapy”. ACS Biomaterials Science and Engineering 2 (2025): 958-980.
5. Quérat L and Chen E. “Self-monitoring of intraocular pressure with ICARE® HOME2 and a smartphone application: Feasibility and acceptability”. Acta Ophthalmologica1 (2025): 109-114.
6. Xu H., et al. “Conformationally restricted Grp94-selective inhibitors”. ACS Omega1 (2025): 449-455.
7. Bui TTM., et al. “Discovery of dual ROCK1/2 inhibitors from Nocardiopsis sp. under metal stress”. ACS Chemical Biology 2 (2025): 432-441.
8. Ferreira AAM., et al. “Advancements and Prospects in Nanorobotic Applications for Ophthalmic Therapy”. ACS Biomaterials Science and Engineering 2 (2015): 958-980.
9. Xu Z., et al. “Modified penetrating deep sclerectomy versus conventional trabeculectomy for the treatment of glaucoma: A 12-month randomized prospective study”. Acta Ophthalmologica (2025).
10. Rodríguez-Ramírez KT., et al. “Neuroprotection of retinal ganglion cells by agonism of the beta but not the alpha estrogen receptor in the axotomized retina”. Acta Ophthalmologica (2025).
11. Freiberg J., et al. “Longitudinal associations of retinal vessel morphology with intraocular pressure and blood pressure”. Acta Ophthalmologica1 (2025): 33-42.
12. Somerville MM., et al. “Role of microglia in glaucomatous pathology”. Advances in Experimental Medicine and Biology 1468 (2025): 149-153.
13. Sanni Isiaka Oluwasegun and MC OD. “Use of Dyop Colors Test for Color Acuity Assessments. Visual Considerations in Managing the Dizzy Patient: A Case Series”. (2023).

Citation

Citation: Isiaka Sanni Oluwasegun. “Advances in Glaucoma Management: A Multiparametric and Technological Approach".Acta Scientific Ophthalmology 8.6 (2025): 01-03.

Copyright

Copyright: © 2025 Isiaka Sanni Oluwasegun. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.